

FOI Request re Non-Small Cell Lung Cancer (NSCLC) Patients

Please provide the following information relating to NSCLC¹ patients treated² by your Trust in the 3 months, **July 2018 to September 2018** inclusive.

If data is not held in a sufficient way within your Trust systems, i.e. if for example you are unable to distinguish between cancer type and/or stage, please indicate accordingly within the tables below.

	Total number treated Stage IIIB/IV NSCLC Patients	If unable to provide number of stage IIIB/IV NSCLC patients treated, please indicate the level at which data has been provided:	
Patients with NSCLC Stage IIIB/IV (Stage 3b/4) ³	6/37	Total number NSCLC patients	43
		Other (please specify)	
		Data not held/accessible	

Of the Stage IIIB/IV NSCLC patients, please indicate the number of patients treated by your Trust in the 3 months **July 2018 to September 2018** inclusive, with the following therapies.

	Total number treated Stage IIIB/IV NSCLC Patients	If unable to provide number of stage IIIB/IV NSCLC patients treated, please indicate the level at which data has been provided:	
Docetaxel (mono or combination therapy)	0/1	Total number NSCLC patients	1
		Other (please specify)	
		Data not held/accessible	
Atezolizumab (Tecentriq)	3/12	Total number NSCLC patients	15
		Other (please specify)	
		Data not held/accessible	
Nivolumab (Opdivo)	0/1	Total number NSCLC patients	1
		Other (please specify)	
		Data not held/accessible	
Pembrolizumab (Keytruda)	3/23	Total number NSCLC patients	26
		Other (please specify)	
		Data not held/accessible	

If your trust does not treat these cancers and you refer your patients to another trust, please state to which trust(s) patients are referred:

¹ ICD10 C33, C34

² Please indicate the number of patients (excluding clinical trial patients) treated with any active anti-cancer drug treatment.

³ TNM staging for Stage IIIB NSCLC = Any T, N3, M0 or T4, N2, M0; TNM staging for Stage IV NSCLC = Any T, any N, M1

Please include number for both those patients that present at stage III/IV and also those whose cancer has progressed to stage III/IV